Immunotherapy for Advanced HCC: Case Series Podcast Pearls

In this downloadable PDF transcript from a CCO podcast, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations for hepatologists, oncologists, and other HCPs in the contemporary use of immune checkpoint inhibitors for treating specific patient cases with advanced hepatocellular carcinoma.
Lipika Goyal, MD
Amit G. Singal, MD, MS
Format: Adobe Acrobat (.pdf)
File Size: 207 KB
Released: May 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Expert commentary on the use of PARP inhibitors in the treatment of pancreatic cancer, from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Released: October 5, 2021

Updated results from CheckMate 649 confirm OS benefit of addition of nivolumab to first-line chemotherapy in gastroesophageal cancers, from ESMO 2021 as reported by Clinical Care Options (CCO)

Released: September 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue